Miyazawa Keika, Otsuka Yuji, Ishiguro Yoshiki
Department of Anesthesiology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Perfusion. 2016 Nov;31(8):709-710. doi: 10.1177/0267659116670717. Epub 2016 Oct 6.
: For a patient with lupus anticoagulant (LA), activated coagulation time (ACT) was measured with two different types of devices (HEMOCHRON 801 and HEMOCHRON Jr).
: ACTs during heparinization measured with the HEMOCHRON 801 were over the range of measurement, while those with the HEMOCHRON Jr. reflected an almost normal response to heparin.
: The phospholipid contained in an activating agent of the HEMOCHRON Jr was suggested to have counteracted the effect of LA.
: It was indicated that the coagulation status for LA-positive patients might be better assessed by ACT measured with phospholipid in an activating agent, although careful interpretation is required.